Ampersand Capital Partners Makes Growth Investment in Vibalogics GmbH

Recipharm AB Acquires Vibalogics from Ampersand Capital Partners

February 18, 2022

Biotechnology

Recipharm AB, a global CDMO based in Sweden, has agreed to acquire Vibalogics, a virotherapy-focused CDMO and Ampersand Capital Partners portfolio company. The deal expands Recipharm's capabilities into viral vaccines, viral vectors and oncolytic virus manufacturing while Vibalogics will continue operating from its Boxborough, MA and Cuxhaven, Germany facilities.

Ampersand Capital Partners Makes Growth Investment in VIVEbiotech

December 4, 2024

Biotechnology

Ampersand Capital Partners has made a growth equity investment in VIVEbiotech to support expansion of the company’s lentiviral vector development and GMP manufacturing capabilities in San Sebastián, Gipuzkoa, Spain. The investment will fund capacity growth and execution of VIVEbiotech’s pipeline of customer projects for cell and gene therapy developers, and industry veteran Dr. Stefan Beyer has been named Chairman.

Ampersand Capital Partners Invests in Genezen Laboratories

January 5, 2021

Biotechnology

Ampersand Capital Partners has made a majority growth-equity investment in Genezen Laboratories, a cell and gene therapy CDMO, to fund completion of a 25,000 sq. ft. cGMP lentiviral vector production facility and expand process development and analytical testing capabilities. The capital will support Genezen's capability expansion across upstream/downstream processing, analytical testing, and cGMP vector production to serve early‑phase and growth-stage cell and gene therapy developers.

Ampersand Capital Partners Acquires Biologos LLC

March 19, 2024

Biotechnology

Ampersand Capital Partners, a healthcare-focused private equity firm, has acquired Biologos LLC, a Glendale Heights, Illinois-based manufacturer of custom and standard cell culture media, reagents, buffers, enzymes, and sera. Ampersand will invest to expand Biologos' capabilities, product offerings, and geographic reach, and has appointed Frank Witney as Chairman with two Ampersand principals joining the board.

Ampersand Capital Partners Makes Growth Investment in GeneWerk GmbH

September 21, 2020

Biotechnology

Ampersand Capital Partners has made a majority growth equity investment in GeneWerk GmbH to expand the company's cell and gene therapy testing capabilities and support U.S. and European market expansion. GeneWerk, a Heidelberg-based clinical and preclinical testing laboratory known for vector integration site analysis and bioinformatics services, will use the capital to scale capabilities and meet rising demand for cell and gene therapy testing.

Ampersand Capital Partners Leads $18.5M Growth Investment in Genezen

November 2, 2023

Biotechnology

Genezen closed an $18.5 million follow-on growth equity financing led by Ampersand Capital Partners to accelerate expansion of its viral vector development and GMP manufacturing capabilities. The capital will support build-out and technology investments at Genezen's facilities (including the Fishers, Indiana GMP viral vector site) to scale retroviral, lentiviral and AAV vector production and support additional customer programs.